휴마시스
205470KOSDAQ61.8 / 100
Reference Date: 2026-09-08
Company InformationBased on 2025 Annual Report
Business Overview
HumaSys operates in three main business segments: POCT immunoassay reagents for in vitro diagnostics, production of male condoms and medical devices, and entertainment services. The POCT division focuses on improving diagnostic products for COVID-19 and HIV, while the rubber products division produces a range of items according to international standards. The entertainment division generates revenue through artist management and content production. Major revenue streams come from POCT (13.4%), rubber products (19.5%), and entertainment services (46.2%).
Number of Employees
64people
Average Salary
47.6M KRW
Score Calculation Basis
Detailed Financial Score
Half of industry avg (excellent)
Well below industry avg
Half of industry avg (excellent)
Avg ▲51.1% (2-year basis)
Avg ▲39.9% (2-year basis)
Avg ROE -13.2% (improving, 3yr)
Detailed News Sentiment
- Neutral남궁견 회장 측 "휴마시스 소액주주 김씨, 3억 투자손실에 '50억 위...
소송 관련 주장이 제기되었으나 직접적인 재무적 영향이나 주가 변동 정보는 제공되지 않았습니다.
- Negative남궁견 회장 "휴마시스 주주 김모씨, 주식 투자손실에 '위자료 50억'...
휴마시스 관련 소송으로 인한 주주 손실 우려 증가.
- Neutral남궁견 전 휴마시스 회장 측 "소액주주 고소 배경 규명돼야…민·형사....
소송 배경에 대한 수사 필요성 언급으로 인해 휴마시스에 대한 직접적인 긍정 또는 부정 영향은 제한적.
Detailed Momentum
52w upper range (71%)
1m +40.96% (strong rise)
Volume dry-up
Detailed Disclosure
- Neutral주식등의대량보유상황보고서(일반)2026-09-04
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-04
- Neutral주식등의대량보유상황보고서(일반)2026-08-28
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-28
- Neutral주식등의대량보유상황보고서(일반)2026-08-24
